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Background The mechanisms leading to the
development of functional motor symptoms (FMS) are of
pathophysiological and clinical relevance, yet are poorly
understood.
Aim The aim of the present study was to evaluate
whether impaired emotional processing at the cognitive
level (alexithymia) is present in patients affected by FMS.
We conducted a cross-sectional study in a population of
patients with FMS and in two control groups (patients
with organic movement disorders (OMD) and healthy
volunteers).
Methods 55 patients with FMS, 33 patients affected
by OMD and 34 healthy volunteers were recruited. The
assessment included the 20-item Toronto Alexithymia
Scale (TAS-20), the Montgomery-Asberg Depression
Rating Scale, the Reading the Mind in the Eyes’ Test and
the Structured Clinical Interview for Personality Disorders.
Results Alexithymia was present in 34.5% of patients
with FMS, 9.1% with OMD and 5.9% of the healthy
volunteers, which was signiﬁcantly higher in the FMS
group (χ2 (2)=14.129, p<0.001), even after controlling
for the severity of symptoms of depression. Group
differences in mean scores were observed on both the
difﬁculty identifying feelings and difﬁculty describing
feelings dimensions of the TAS-20, whereas the
externally orientated thinking subscale score was similar
across the three groups. Regarding personality disorder,
χ2 analysis showed a signiﬁcantly higher prominence of
obsessive-compulsive personality disorder (OCPD) in the
FMS group (χ2 (2)=16.217, p<0.001) and 71.4% of
those with OCPD also reached threshold criteria for
alexithymia.
Conclusions Because alexithymia is a mental state
denoting the inability to identify emotions at a cognitive
level, one hypothesis is that some patients misattribute
autonomic symptoms of anxiety, for example, tremor,
paraesthesiae, paralysis, to that of a physical illness.
Further work is required to understand the contribution
of OCPD to the development of FMS.
INTRODUCTION
Functional motor symptoms (FMS), which include
abnormal movements and weakness, are part of the
wide spectrum of functional neurological symp-
toms, one of the commonest diagnoses made in
neurological practice.1 Patients affected by FMS
have levels of disability, distress and healthcare
usage that equals, and in some cases surpasses,
patients with neurodegenerative disease.2
Recent years have seen a surge of research inter-
est in functional neurological symptoms. One
outcome has been a reduction in the emphasis on
identiﬁable traumatic events (such as sexual abuse
in childhood or adult life, remote or recent life
events) being antecedents to the development of
FMS. Several studies have demonstrated that such
traumatic events, although clearly important, might
not play a unique role in the aetiology of FMS3 4,
and, in the most recent revision of the Diagnostic
and Statistical Manual of Mental Disorders
(DSM-5),5 the presence of a psychological stressor
has been downgraded from an essential to a sup-
portive criterion for the diagnosis of conversion
disorder (functional neurological symptom
disorder).6
Recent cognitive and neurobiological models of
the pathophysiology of functional neurological
symptoms have concentrated more on ‘how’ symp-
toms might be produced than on ‘why’. Research
ﬁndings have identiﬁed three putative mechanistic
processes leading to functional movement disorders
(FMDs): abnormal attentional focus,7 abnormal
beliefs and expectations,8 and abnormalities in
sense of agency.9 These three processes have been
combined in recent neurobiological models where
abnormal predictions related to movement or per-
ception are triggered by self-focused attention, and
the resulting percept or movement is generated
without a normal sense of agency.10 11
Recent aetiological work has highlighted a pos-
sible role for physical precipitating factors in the
triggering of functional neurological and other
somatic symptoms, and in some cases clear links
have been made between the nature of the physical
precipitant and the phenomenology of the resulting
functional symptom.12 However, the physical preci-
pitants identiﬁed (minor injury, ﬂu-like illness, diar-
rhoea, migraine) are very common in the healthy
population, and therefore why they should trigger
functional symptoms in only a small proportion of
people remains unexplained. Therefore, the investi-
gation of mechanistic factors in the development of
functional neurological symptoms is of continued
relevance and importance.
One clue has been the observation that physio-
logical markers of panic or anxiety are often
reported at onset of FMSs (eg, in association with a
physical trigger) or in a persistent manner through-
out the illness, but that patients only rarely report a
concurrent emotional state of anxiety.13 These
studies in patients with FMSs link to previous work
in patients with non-epileptic attacks where often
patients will report or be observed to have physio-
logical changes seen in panic episodes but generally
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do not report feeling ‘panicked’. This phenomenon has been
named as ‘non-fearful panic’.14
Failure to identify and describe emotions in oneself and a dif-
ﬁculty in distinguishing and appreciating the emotions of others
is called alexithymia, a term coined by Sifneos (1973) to
describe certain clinical characteristics observed among patients
with psychosomatic disorders who had difﬁculty engaging in
insight-oriented psychotherapy.15 Most previous studies of alex-
ithymia in patients with functional neurological symptoms have
been restricted to non-epileptic seizures (NES).16 17 Here, both
patients with epilepsy and those with NES had similar but very
high rates of alexithymia. Only one recent study has assessed
the prevalence of alexithymia in a general group of conversion
disorders, and this found higher rates in patients compared with
controls.18 No studies have previously investigated the preva-
lence of alexithymia in a population solely of patients affected
by FMSs. We were speciﬁcally interested in assessing this, as
high rates of alexithymia could help provide an explanation for
the clinical observation of a dissociation between patients’
endorsement of physiological markers of panic/anxiety and their
denial of the emotional experience of panic/anxiety.
The aim of the present study was to evaluate the prevalence
of alexithymia in patients affected by FMS and to clarify its
pathophysiological role. In addition, we determined the pres-
ence of other mental states that may confound the interpretation
of alexithymia, namely, personality disorder (PD), depression
and deﬁcits in theory of mind indicative of impaired social cog-
nition. To do this we conducted a cross-sectional study in a
population of patients with FMS presenting to a neurological
service for the ﬁrst time and in two control groups (patients
with organic movement disorders (OMD) and healthy controls).
MATERIALS AND METHODS
Subjects
Patients affected by FMS and OMD were recruited from neuro-
psychiatry and neurology outpatient clinics at the National
Hospital for Neurology and Neurosurgery (NHNN), London,
UK. Fifty-ﬁve patients affected by FMS assessed at NHNN
between January and July 2013 were included in the study, and
they were compared with 33 age-matched and sex-matched
patients with a diagnosis of OMD and 34 age-matched and sex-
matched healthy controls. Patients with FMS were included if
they had ‘clinically deﬁnite’19 FMS. We used the Fahn &
Williams criteria for movement disorders, and, for functional
weakness, we used the DSM IV A, C, D and E Conversion
Disorder criteria. The diagnosis was ascertained by a neurologist
and psychiatrist on the basis of clinical presentation and appro-
priate investigations. We did not select cases based on aetio-
logical assumptions (eg, presence of psychological factors);
rather we decided to focus on the motor symptoms themselves
to formulate a positive diagnosis. Patients affected by OMD
were included after receiving a diagnosis by a consultant neur-
ologist at the NHNN. Healthy individuals mainly comprised
hospital staff and visitors to the hospital.
Exclusion criteria
Exclusion criteria for all the three groups were (i) age less than
18 years; (ii) inability to communicate with the researcher or
complete questionnaires because of language difﬁculties, severe
learning disabilities or dementia; (iii) any other serious neuro-
logical or medical illnesses; and (iv) the presence of both a func-
tional and an OMD (functional overlay).
All subjects were assessed by a neuropsychiatrist (BD) at the
NHNN. Demographic information was obtained from each
participant through a brief self-report questionnaire designed
for the study.
Assessments
▸ The 20-item Toronto Alexithymia Scale (TAS-20): This is a
well-validated and commonly used measure of alexithymia;20
it is a multidimensional self-report instrument with a three-
factor structure: difﬁculty identifying feelings (DIF), difﬁ-
culty describing feelings (DDF) and externally orientated
thinking (EOT). As well as comparing TAS scores across the
groups, we took the suggested TAS criterion score of ≥61 as
categorically denoting alexithymia.
▸ The Montgomery-Asberg Depression Rating Scale
(MADRS): This is a 10-item semistructured clinician-rated
interview widely used to measure levels of depression; it has
been showed to yield reliable and internally consistent scores
and to demonstrate criterion-related validity.21
▸ The Reading the Mind in the Eyes’ Test (Eyes): This is an
advanced test of theory of mind. It is widely used to assess
individual differences in social cognition and emotion recog-
nition across different groups and cultures. Although it is not
a diagnostic instrument, several studies indicate that the Eyes
is a reliable instrument for assessing social cognition in
adults.22
▸ The Structured Clinical Interview for Personality Disorders
(SCID II): This is a semistructured assessment instrument for
PDs. Several studies have shown that it is reliable, internally
consistent and valid.23
Ethical approval was obtained from the UCL Institute of
Neurology and National Hospital for Neurology Joint Ethics
Committee, and all participants provided written informed
consent.
Analysis
Statistical analysis was performed using Statistical Package for
Social Science (SPSS V.21). The variables were ﬁrst tested for
normality using the Shapiro–Wilks test. The variables that were
not normally distributed (p<0.05) were log10-transformed. For
continuous data, a one-way analysis of variance (ANOVA) was
used to test for differences across the three groups with posthoc
Bonferroni pairwise comparisons when signiﬁcant. The χ2 test
was used for categorical data. Bonferroni correction was applied
to correct for multiple comparisons. Analyses of covariance
(ANCOVA) were carried out using scores from the MADRS and
the Eyes as covariates where appropriate.
RESULTS
In total, 55 patients with FMS (42 of 55 females (76%); mean
age 43 years (SD, 10.55 years)), 33 patients with OMD (23 of
33 females (70%); mean age 45.70 years (SD, 14.64 years)) and
34 healthy controls (23 of 34 females (68%); mean age
42.18 years (SD, 11.32 years)) were included in the study.
Patients’ clinical characteristics are shown in table 1. Age and
gender were not signiﬁcantly different between the three groups
(age: F (2, 119)=0.809, p=0.448; gender: χ2 (2)=0.927,
p=0.629).
There was a signiﬁcant difference in TAS-20 alexithymia
scores between the three groups (F (2, 119)=20.467, p<0.001),
as shown in table 2. Posthoc analysis showed that each pairwise
comparison was signiﬁcant (FMS vs OMD: p=0.031; FMS vs
healthy controls: p<0.001; OMD vs healthy controls:
p=0.003). Alexithymia was present in 34.5%, 9.1% and 5.9%
of the FMS, OMD and healthy control groups, respectively. The
proportions of alexithymic patients (TAS-20≥ 61) differed
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signiﬁcantly between groups (χ2 (2)=14.129, p<0.001).
Comparisons between groups showed a signiﬁcantly increased
proportion of high-alexithymic subjects in patients with FMS
(34.5%) as compared with patients with OMD (9.1%; χ2 (1)
=7.127, p=0.08) and healthy controls (5.9%; χ2 (2)=89.000,
p<0.01).
Mean scores on the Eyes test and MADRS are shown in
table 3. One-way ANOVA on the Eyes test did not show a
signiﬁcant effect of group (F (2, 119)=1.052, p=0.353). For
the MADRS, there was a signiﬁcant main effect of group (F
(2, 119)=11.455, p<0.001). Posthoc pairwise comparisons
revealed signiﬁcant differences between patients with FMS and
patients with OMD (p=0.007) and patients with FMS and
healthy controls (p<0.000). Signiﬁcant differences on total
alexithymia scores remained when MADRS score was entered as
a covariate using ANCOVA (F (3, 121)=26.636, p<0.001).
Group differences were observed in both the DIF and DDF
dimensions of the TAS-20, whereas the EOT subscale appeared
relatively consistent across the three groups, as shown in table 2.
One-way ANOVA on the DIF subscale scores showed a signiﬁ-
cant main effect of group (F (2, 119)=13.383, p<0.001).
Posthoc pairwise comparisons revealed signiﬁcant differences
between patients with FMS and patients with OMD (p=0.025)
and between patients with FMS and healthy controls
(p<0.001). However, no signiﬁcant difference was observed
between patients with OMD and healthy controls (p=0.102).
One-way ANOVA on the DDF subscale also demonstrated a sig-
niﬁcant main effect of group (F (2, 119)=26.281, p<0.001).
Pairwise comparisons revealed signiﬁcant differences between
patients with FMS and patients with OMD (p=0.006), patients
with FMS and healthy controls (p<0.001), and patients with
OMD and healthy controls (p=0.001). With respect to the
EOT dimension, one-way ANOVA revealed a non-signiﬁcant
effect of group (F (2, 119)=2.088, p=0.128). ANCOVA with
MADRS score as a covariate was performed in order to detect
any effect of depression on the DIF and DDF subscales, with
results showing that depression did not act as a signiﬁcant con-
founding factor (F (3, 121)=18.549, p<0.001 for DIF; F (3,
121)=33.727, p<0.001 for DDF).
Correlations between TAS-20 total score, TAS-20 subscores
and the Eyes score were not signiﬁcant (range of r=−0.126 to
0.006).
Regarding PDs, the prevalence of each subtype is shown in
table 4. χ2 Analysis showed a signiﬁcant difference only in the dis-
tribution of obsessive-compulsive personality disorder (OCPD) (χ2
(2)=16.217, p<0.001) within the three groups. The presence of
OCPD was found to strongly correlate with the presence of alex-
ithymia (r=0.283, p=0.002); in fact, 71.4% of patients who had
OCPD were also alexithymic. Comparisons between groups
showed a signiﬁcantly increased proportion of OCPD in patients
with FMS as compared with patients with OMD (χ2 (1)=9.989,
p=0.02) and healthy controls (χ2 (1)=7.600, p=0.006).
DISCUSSION
Alexithymia
Our data suggest that patients affected by FMS are signiﬁcantly
more alexithymic than patients with OMDs and healthy con-
trols, with a third of FMS patients reaching full criteria for alex-
ithymia. The prevalence of alexithymia still remained
signiﬁcantly higher in patients with FMS even after controlling
for symptoms of depression. The relationship between alexithy-
mia and depression has been widely described, and it is well
documented that alexithymia represents a risk factor for the
development of depressive disorders.24 However, we found
alexithymia to be a signiﬁcant marker for FMS, independent of
the presence of symptoms of depression. With respect to the
three subscales of the TAS-20, patients with FMS were signiﬁ-
cantly more alexithymic on factor I (DIFs) and II (DDFs),
whereas we did not ﬁnd a signiﬁcant difference on factor III
(EOT). According to De Gucht et al,25 the internal consistency
of the EOT subscale is considerably lower than that of the two
other subscales, suggesting that a two-factor approach, rather
than a three-factor one, could be more appropriate to measure
alexithymia. It may also be the case that for patients with FMS,
difﬁculty in identifying and explaining emotions relates only to
the self, and not generally to the understanding of the emotional
states of others. As additional evidence for this interpretation,
patients with FMS were not signiﬁcantly different from controls
Table 2 Toronto Alexithymia Scale (TAS-20) total scores,
percentage reaching criteria for presence of alexithymia (>60) and








TAS-20 score mean (SD) 55.38 (12.12) 49.19 (9.13) 40.79 (8.54) <0.002
TAS-20 < 51 n (%) 24 (43.6) 19 (57.6) 31 (91.2) <0.002
TAS-20=52–60 n (%) 12 (21.8) 11 (33.3) 1 (2.9) <0.003
TAS-20 > 61 n (%) 19 (34.5) 3 (9.1) 2 (5.9) <0.001
DIF mean (SD) 14.42 (4.5) 12.06 (3.8) 9.97 (3.1) <0.003
DDF mean (SD) 21.22 (5.8) 17.48 (5.4) 12.74 (4.4) <0.002
EOT Mean (SD) 19.76 (4.6) 19.85 (3.6) 18.06 (4.0) 0.128
DDF, difficulty describing feeling; DIF, difficulty identifying feelings; EOT, externally
orientated thinking; FMS, functional motor symptoms; OMD, organic movement
disorders.









Tremor 12 (21.8%) 2 (6.1%)
2 essential tremor
Myoclonus 12 (21.8%) 2 (6.1%)
2 cortical myoclonus
Dystonia 12 (21.8%) 27 (81.8%)
15 cervical dystonia
12 focal hand dystonia
Weakness 16 (29.1%) 2 (6.1%)
1 transverse myelitis
1 motor neuron disease
Gait 1 (1.8%)
Tic 2 (3.6%)








MADRS score mean (SD) 10.65 (7.5) 6.27 (5.8) 4.32 (4.59) <0.002
Eyes score mean (SD) 23.38 (4.3) 22.73 (4.1) 24.21 (3.9) 0.353
FMS, functional motor symptoms; MADRS, Montgomery-Asberg Depression Rating
Scale; OMD, organic movement disorder.
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on the Eyes test, suggesting that the ability to recognise emo-
tional expressions and the capacity to determine the mental
state of an individual based on a partial facial expression (mea-
sures of social cognition) are not compromised in patients with
FMS. Similar results regarding Theory of Mind have been
found recently by Stonnington et al26 in a population of
patients affected by conversion disorders.
In the last few years, several studies have examined the rela-
tionship between alexithymia and functional neurological symp-
toms, mainly focusing on NESs. The most common ﬁnding is
that patients with NESs are no more likely to have alexithymia
than patients with epileptic seizures;16–27 one study has found
an increased prevalence in NES,28 although another suggests
that emotional dysregulation, including alexithymia, may
pertain to a small subgroup.29 Only one study has assessed alex-
ithymia in other functional disorders.18 This study differs from
ours in several important ways: they grouped together all types
of functional neurological disorder, they used a single compari-
son group of healthy controls and they did not assess comorbid-
ities. Nevertheless, they too found a higher rate of alexithymia
in patients than controls, although this was higher than ours
(74.5%), and they also found that this pertained to the DIF and
DDF factors only.
Previous studies have reported the prevalence of alexithymia
in the general population as approximately 10%.30 This tallies
with that of our OMD group (9.1%) but is higher than our
healthy controls (5.9%). The discrepancy in the prevalence of
alexithymia between our control sample and the control
samples of previous studies could be due to the relatively small
size of this group. Alternatively, it could be related to the use of
hospital staff as controls subjects—alexithymia has been shown
to be linked to the level of education and socioeconomic status
that may have differed between the groups.24
Personality disorders
Our data also showed a signiﬁcantly increased proportion of
OCPD in patients with FMS as compared with patients with
OMD and healthy controls. Previous studies have already under-
lined the role of PD as a risk factor for the onset and mainten-
ance of both FMS31 and NES,32 but no studies to date have
found higher prevalence speciﬁcally of OCPD in patients with
functional neurological symptoms. Feinstein et al31 found a
prevalence of PD of 42% in their sample of patients affected by
FMDs; these were mostly antisocial, borderline and dependent
PDs. Similar results were found by Howarka et al32 and by
Reuber et al33 in patients affected by NES: both studies found
high rates of borderline PDs in patients with NES. On the other
hand, Kranick et al,13 who assessed personality traits in a popu-
lation of patients affected by FMDs using the Revised
Neuroticism-Extroversion-Openness Personality Inventory, a
dimensional instrument, did not ﬁnd any signiﬁcant difference
in their group of patients compared with healthy controls. This
discrepancy might be consistent with the observation that differ-
ent forms of functional neurological symptoms (NESs, func-
tional weakness or movements) may be associated with different
personality traits (assessed by categorical instruments).
Our results, showing a higher prevalence of OCPD in patients
with FMS, are in contrast with the results of the abovementioned
studies. Although our study has been conducted with a relatively
small sample of patients, it differs signiﬁcantly from that of
Feinstein et al,31 which has no comparative control group, and
Kranick et al,13 which has used just a dimensional instrument.
Further studies are needed to clarify the prevalence of each
subtype of PD in a bigger population of patients with FMS.
In our study, there was a large overlap between OCPD and
alexithymia with 10 of 14 OCPD patients also meeting criteria
for alexithymia. This suggests that both scales may be measuring
similar traits. However, this is unlikely to be the explanation as
the TAS asks almost exclusively about emotions, whereas the
SCID focuses on thoughts and behaviour. Nevertheless, alex-
ithymia as a construct does include features overlapping with
those of OCPD. For example, early studies described patients
with psychosomatic symptoms developing compulsive beha-
viours and ‘a life guided by rules and regulations’ as well as
emotional disconnection.34 Nemiah et al35 showed that alex-
ithymia is characterised by (i) DIFs, differentiating among the
range of common affects, and distinguishing between feelings
and the bodily sensations of emotional arousal; (ii) difﬁculty
ﬁnding words to describe feelings to other people; (iii) con-
stricted imaginal processes, as evidenced by a paucity or absence
of fantasies referable to drives and feelings; and (iv) a thought
content characterised by a preoccupation with the minute
details of external events. This therefore suggests that OCPD
may not be an independent risk factor for the development of
functional motor disorder and that alexithymia is a more rele-
vant personality construct for understanding the mechanism of
developing functional symptoms. However of relevance is that
Kang et al36 have recently found an overlap between alexithy-
mia and obsessive-compulsive disorder with 41% comorbidity.
To clarify this further, future studies should include an assess-
ment of obsessive-compulsive disorder, as well as OCPD.
Integration with current neurobiological models
How might alexithymia be a relevant mechanistic factor for the
development of FMS? We have discussed above the evidence
that patients with FMS frequently report physiological markers
of panic and anxiety, without reporting an emotional state of
anxiety. These data are complemented by evidence that patients
with FMS have greater arousal as indicated by galvanic skin
response, higher baseline cortisol, reduced heart rate variability,
greater threat vigilance and greater startle response to arousing
stimuli.37 38 Patients with FMS have been found to have greater
amygdala activity in response to arousing stimuli and impaired
habituation along with greater functional connectivity between
the amygdala and supplementary motor areas.39 We speculate











n (%) p Value
Avoidant 2 (3.6) 0 (0) 0 (0) 0.290
Dependent 2 (3.6) 0 (0) 0 (0) 0.290
Obsess-compulsive 14 (25.4) 0 (0) 1 (2.9) <0.001
Passive-aggressive 2 (3.6) 0 (0) 1 (2.9) 0.554
Depressive 3 (5.4) 0 (0) 0 (0) 0.154
Paranoid 3 (5.4) 0 (0) 0 (0) 0.154
Schizotypal 0 (0) 1 (3) 0 (0) 0.257
Schizoid 2 (3.6) 1 (3) 0 (0) 0.543
Histrionic 0 (0) 1 (3) 0 (0) 0.257
Narcissistic 2 (3.6) 0 (0) 0 (0) 0.290
Borderline 3 (5.4) 1 (3) 0 (0) 0.372
Antisocial 1 (1.8) 0 (0) 0 (0) 0.541
FMS, functional motor symptoms; OMD, organic movement disorder; PD, personality
disorder.
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that the autonomic arousal occurring during a physical precipi-
tating event, or more chronically, fails to be interpreted correctly
as anxiety/panic in patients with an impairment in the cognitive
processing of emotional arousal (ie, alexithymia). These sensa-
tions may instead be interpreted as symptoms of physical illness
because of an attribution of sensations to organic rather than
psychological or benign causes. This vicious cycle might be
further fostered in patients with pronounced obsessive-
compulsive personality traits. In fact, the pervasive pattern of
mental controlling and checking, at the expense of ﬂexibility
and openness,5 might reinforce the patient’s belief of illness and
exaggerated focus on physical symptoms. Individuals suffering
from obsessive-compulsive traits often are not in touch with
their emotional states as much as their thoughts. This interpret-
ation, shown in ﬁgure 1, links directly to the key concepts pro-
posed in the neurobiology of FMS: symptom-related beliefs/
expectations and symptom/self-directed attention.40
Relevance for management
Considering alexithymia as a risk factor for the development of
FMS might help the specialist not only in the deﬁnition of the
diagnosis but also in the communication of the diagnosis. For
example, communicating the diagnosis to a FMS patient who is
alexithymic and completely focused on his/her physical symp-
toms might beneﬁt from a more physical explanation rather
than from a pure psychological one. In addition, there are
several potential implications for treatment, particularly with
respect to use of psychological therapies. First, a psychological
treatment in a patient with alexithymia requires speciﬁc skills.
Previous work has suggested that alexithymia is a negative prog-
nostic indicator for many psychological treatments, particularly
those focusing on insight, emotional awareness and a close
alliance with a therapist.41 In contrast, alexithymia may not
affect more structured cognitive-behavioural treatments and may
even be associated with better outcomes of such treatments. It
has been hypothesised that the compulsive nature and external
focus of people with alexithymia prompt greater adherence to
structured exercises and behavioural recommendations. With
regards to the prognosis, although to date no studies have been
conducted assessing the inﬂuence of alexithymia on FMS prog-
nosis, it has been shown that alexithymia predicts poorer out-
comes of treatment for anxiety and somatoform disorders,
depression and functional gastrointestinal disorders.41
Limitations
We acknowledge the limits of our study: ﬁrst, we did not conduct
a systematic interview for Axis I psychiatric disorders to establish
diagnoses of affective and anxiety disorders. In particular, we did
not assess the prevalence of anxiety symptoms in our samples—
anxiety might be a confounding factor for alexithymia, which we
were unable to address.42 Second, this study is limited by the lack
of a disability-matched OMD control group as 81% of patients
had a diagnosis of dystonia, which is not representative of all
movement disorders. Third, the choice of some scales might be
criticised: although the TAS-20 is the most widely used instru-
ment for assessing alexithymia, the use of a self-reported scale
might be not appropriate, as alexithymic patients are not very
self-reﬂective; with respect to the assessment of PD, it might have
been more appropriate using a double instrument (categorical
and dimensional approach), rather than just a categorical one.
Fourth, the design of our study, a cross-sectional one, does not
allow direct interpretation of causality.
CONCLUSIONS
The associations between alexithymia, OCPD and FMS are
potentially relevant for understanding the mechanism develop-
ing functional neurological symptoms, the diagnostic explan-
ation given to patients and treatment. As our study examined
patients solely with functional movement symptoms, further
studies are needed to clarify the prognostic role of alexithymia
in patients affected by other forms of functional neurological
symptoms.
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